In­novent and Lil­ly win sec­ond Chi­na OK for Tyvyt in front­line NSCLC, ramp­ing up pres­sure on king Keytru­da

In­novent Bi­o­log­ics and its part­ners at Eli Lil­ly have notched an­oth­er ar­row in their quiver in their bid to take down Mer­ck’s Keytru­da.

Chi­nese reg­u­la­tors grant­ed a promi­nent new ap­proval for the pair’s Tyvyt on Wednes­day, in­di­cat­ing the drug for first-line treat­ment of non­squa­mous non-small cell lung can­cer in com­bi­na­tion with peme­trexed and plat­inum chemo. It’s the sec­ond ap­proval in the coun­try for the Chi­nese pow­er­house and Amer­i­can Big Phar­ma, af­ter Tyvyt was OK’ed in 2018 for re­lapsed or re­frac­to­ry clas­si­cal Hodgkin’s lym­phoma af­ter two lines of chemother­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.